Careers at CAPTIS
Log In / Sign In ▼
Register w/out LinkedIn
Login w/out LinkedIn
🔒 MEMBER AREA ▼
☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS
You are a Business
You are a Healthcare Executive
Dealing with CAPTIS
Candidate Contact Form
Log in (Existing Account)
WW Trade Shows
Plastic & Aesthetic Surgery
Wall Street Beat
Business/Financial News
Musculoskeletal News Roundup
M&A Activity
CAPTIS Magazine
@CaptisCorp Twitter Timeline
CAPTIS LinkedIn Timeline
Articles ➜
Healthcare Executive Contact
Apply for a position at CAPTIS
(Cell/Mobile US & Canada Toll Free, or Skype)
(Cell/Mobile Swiss Landline Switchboard, or Skype)
You are here: Home1 / Blog
Egypt fast-track medical device registration pathway speeds up market access timeframes
04/16/2019 /0 Comments/in Blog, Emergo Group /by CAPTIS
By Stewart Eisenhart, Emergo Group
A fast-track premarket review pathway for some medical devices in Egypt is yielding substantially reduced time to market for qualifying manufacturers.
Get the full story here at the Emergo Group's blog.
The opinions expressed in this blog post are the author's only and do not necessarily reflect those of MassDevice.com or its employees.
https://www.captis.com/wp-content/uploads/2019/04/emergo-1x1-7.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-16 03:00:172019-04-16 03:31:08Egypt fast-track medical device registration pathway speeds up market access timeframes
Glaukos touts 5-year study of glaucoma stents
04/15/2019 /0 Comments/in Blog, Clinical Trials, Featured, Glaukos, Implants, Ivantis, News Well, Optical/Ophthalmic, Vision /by CAPTIS
Glaukos (NYSE:GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly fewer iStent patients needed add-on medications after five years, the company said.
The study showed that newly diagnosed, primary open-angle glaucoma (POAG) patients who received two iStents achieved a 35.3% reduction in mean intraocular pressure (IOP) to 16.5 mmHg. The prospective, controlled, multi-surgeon clinical trial pitted evaluated the five-year safety and efficacy of two iStents vs. topical prostaglandin as an initial intervention in POAG subjects who had not had prior glaucoma treatment. A total of 101 subjects were randomized in a 1:1 ratio to receive either two iStents in a standalone procedure or once-daily topical travoprost, a commonly prescribed prostaglandin. The results were published in Ophthalmology Glaucoma.
Treatment success — defined as mean diurnal IOP of 6 mmHg to 18 mmHg without add-on medication or secondary glaucoma surgery — was achieved in 77% of stent eyes vs. 53% of travoprost eyes (p = 0.04). Seventeen percent of stent eyes vs. 44% of travoprost eyes required add-on medication.
The need for add-on medication arose at a slower rate in the stent group than in the travoprost group, especially after two years of follow-up. Study authors observed that from two to five years of follow-up, add-on medications were initiated in roughly double the number of travoprost eyes vs. stent eyes. The safety profile was excellent in both groups throughout follow-up, according to the San Clemente, Calif.-based company.
"Topical ocular hypotensive medications are typical first-line glaucoma therapy but these drugs can be ineffective due to high rates of patient non-adherence, ocular surface damage, cost and other factors," said ophthalmic surgeon and lead author Dr. Robert Fechtner in a prepared statement from Glaukos. "This study shows that not only are Glaukos' iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications."
Three-year outcomes of this study were published in 2016 in Ophthalmology and Therapy. The most recent article detailing five-year outcomes may be accessed online here.
"This latest publication represents the first-ever five-year, protocol-driven, randomized evaluation of standalone iStent implantation in newly diagnosed glaucoma patients," said Glaukos prez & CEO Thomas Burns. "Moreover, it adds meaningful outcomes data to the growing body of peer-reviewed evidence that implantation of a single or multiple iStents can reliably achieve sustained IOP reductions in an elegant, tissue-sparing procedure with a highly favorable safety profile."
Today's announcement was good news for Glaukos, whose iStent recently fared worse in a two-year study that compared it to competitor Ivantis' Hydrus Microstent. The Ivantis study touted reductions in medication use and no reoperations for patients in the Hydrus arm.
https://www.captis.com/wp-content/uploads/2019/04/Glaukosupdated-300x195.jpg 195 300 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-15 11:52:012019-04-15 12:01:14Glaukos touts 5-year study of glaucoma stents
U.K. government requests Brexit deadline extension
By Ronald Boumans, Emergo Group
The U.K. government has requested a further delay in implementing its withdrawal from the European Union, with an April 12 deadline for a no-deal Brexit outcome fast approaching.
https://www.captis.com/wp-content/uploads/2019/04/emergo-1x1-6.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-15 03:00:472019-04-15 03:01:34U.K. government requests Brexit deadline extension
EO plant shutdown leads to pediatric breathing tube shortage
04/12/2019 /0 Comments/in Blog, Business/Financial News, Center for Devices and Radiological Health (CDRH), FDA, Featured, Food & Drug Administration (FDA), Hospital Care, News Well, pediatrics, Respiratory, Smiths Medical, Sterigenics International Inc., Sterilization / Calibration, viant /by CAPTIS
Smiths Medical Bivona tracheostomy tubes are in short supply, according to the FDA. (Image from Smiths Medical)
The February shutdown of an ethylene oxide (EO) sterilization plant has produced the first temporary medical device shortage, according to the FDA.
The device in short supply is the Bivona tracheostomy tube manufactured by Smiths Medical and used by many pediatric patients. The FDA anticipates the tube will be made available again the week of April 22, according to a statement from Dr. Jeffrey Shuren, director of the agency's Center for Devices and Radiological Health (CDRH). The state of Illinois ordered the shutdown of the Sterigenics plant in Willowbrook, Ill. due to emissions of EO, a highly carcinogenic chemical compound.
Get the full story on our sister site, Medical Design & Outsourcing.
https://www.captis.com/wp-content/uploads/2019/04/smiths-medical-bivona_flextend-tracheostemy-tubes-300x195.jpg 195 300 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-12 13:44:092019-04-12 14:01:30EO plant shutdown leads to pediatric breathing tube shortage
Canadian regulators clarify changes in qualifications for medical device licenses following Sterigenics shutdown
Canadian medical device regulator Health Canada has issued a clarification on which changes to Medical Device License (MDL) holders' sterilization processes constitute "significant changes" following the closure of a major sterilization facility in the US earlier in 2019.
https://www.captis.com/wp-content/uploads/2019/04/emergo-1x1-5.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-12 03:00:542019-04-12 03:01:53Canadian regulators clarify changes in qualifications for medical device licenses following Sterigenics shutdown
5 digital health startups you need to watch in 2019
04/11/2019 /0 Comments/in adheretech, Big Data, Blog, Business/Financial News, CarePredict, devotedhealth, Featured, Funding Roundup, Health Information Technology, jointacademy, mediktor, mHealth (Mobile Health), News Well, Software / IT, startuphealth /by CAPTIS
(Image from Unsplash)
Funding for digital health companies continues to rise, with 2018 the biggest year so far this decade, according to healthcare investment firm StartUp Health. Investors took a greater interest in machine learning, blockchain and artificial intelligence (AI).
Digital health funding was 14 times greater than it was eight years ago, when New York-based StartUp Health began tracking these investments. From 2017 to 2018, the average deal size grew by $6 million. Machine learning companies cut 66 deals to raise $940 million, an 80% increase in funding compared to 2017. Patient empowerment received the most funding of any function in 2018, $3 billion across 193 deals.
Here are five of the up-and-coming digital health companies to watch in 2019:
https://www.captis.com/wp-content/uploads/2019/04/Digitalhealthupdated-300x195.jpg 195 300 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-11 13:38:372019-04-11 14:01:235 digital health startups you need to watch in 2019
5 issues for medical device risk management and design controls
By Mark Leimbeck, Emergo Group
Medical device design and development processes in the context of risk management require careful consideration and planning by manufacturers. Following our webinar in early 2019, we explore five key issues companies face when linking design and development with risk management and, ultimately, patient safety.
https://www.captis.com/wp-content/uploads/2019/04/emergo-1x1-4.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-11 03:00:302019-04-11 03:31:055 issues for medical device risk management and design controls
FDA identifies hundreds of device types affected by sterilization facility closures
The US Food and Drug Administration has identified nearly 600 types of medical devices possibly impacted by the recent shutdown of a sterilization facility in the midwestern US, and states that a second sterilization facility will also close this year.
https://www.captis.com/wp-content/uploads/2019/04/emergo-1x1-3.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-10 03:00:252019-04-10 03:01:08FDA identifies hundreds of device types affected by sterilization facility closures
The Nuremberg Code and its impact on clinical research
04/09/2019 /0 Comments/in Blog, IMARC /by CAPTIS
by Natalie Jarmusik, Clinical Research Associate, IMARC Research
The Nuremberg Code is one of the most influential documents in the history of clinical research.
Created more than 70 years ago following the notorious World War II experiments, this written document established 10 ethical principles for protecting human subjects.
We'll take a closer look at its origins, its guidelines and its enduring impact.
What Is the Nuremberg Code?
When World War II ended in 1945, the victorious Allied powers enacted the International Military Tribunal on November 19th, 1945. As part of the Tribunal, a series of trials were held against major war criminals and Nazi sympathizers holding leadership positions in political, military, and economic areas. The first trial conducted under the Nuremberg Military Tribunals in 1947 became known as The Doctors' Trial, in which 23 physicians from the German Nazi Party were tried for crimes against humanity for the atrocious experiments they carried out on unwilling prisoners of war. Many of the grotesque medical experiments took place at the Auschwitz concentration camp, where Jewish prisoners were tattooed with dehumanizing numbers onto their arms; numbers that would later be used to identify their bodies after death.
The Doctors' Trial is officially titled "The United States of America v. Karl Brandt, et al.," and it was conducted at the Palace of Justice in Nuremberg, Bavaria, Germany. The trial was conducted here because this was one of the few largely undamaged buildings that remained intact from extensive Allied bombing during the war. It is also said to have been symbolically chosen because it was the ceremonial birthplace of the Nazi Party. Of the 23 defendants, 16 were found guilty, of which seven received death sentences and nine received prison sentences ranging from 10 years to life imprisonment. The other 7 defendants were acquitted.
The verdict also resulted in the creation of the Nuremberg Code, a set of ten ethical principles for human experimentation.
What Are The Nuremberg Code's Ethical Guidelines For Research?
The Nuremberg Code aimed to protect human subjects from enduring the kind of cruelty and exploitation the prisoners endured at concentration camps. The 10 elements of the code are:
Voluntary consent is essential
The results of any experiment must be for the greater good of society
Human experiments should be based on previous animal experimentation
Experiments should be conducted by avoiding physical/mental suffering and injury
No experiments should be conducted if it is believed to cause death/disability
The risks should never exceed the benefits
Adequate facilities should be used to protect subjects
Experiments should be conducted only by qualified scientists
Subjects should be able to end their participation at any time
The scientist in charge must be prepared to terminate the experiment when injury, disability, or death is likely to occur
Want to learn more about the history of clinical research? Take a minute to watch the video and explore our History of Clinical Research timeline for more detail.
The Significance Of The Nuremberg Code
The Nuremberg Code is one of several foundational documents that influenced the principles of Good Clinical Practice (GCP).
Good Clinical Practice is an attitude of excellence in research that provides a standard for study design, implementation, conduct and analysis. More than a single document, it is a compilation of many thoughts, ideas and lessons learned throughout the history of clinical research worldwide.
Several other documents further expanded upon the principles outlined in the Nuremberg Code, including the Declaration of Helsinki, the Belmont Report and the Common Rule.
Although there has been updated guidance to Good Clinical Practice to reflect new trends and technologies, such as electronic signatures, these basic principles remain the same. The goal has always been—and always will be—to conduct ethical clinical trials and protect human subjects.
https://www.captis.com/wp-content/uploads/2019/04/imarc-1x1-1.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-09 07:26:422019-04-09 07:31:48The Nuremberg Code and its impact on clinical research
Japan increases medical device registration fees
Japan's Pharmaceutical and Medical Devices Agency (PMDA) has increased registration, inspection and related regulatory fees for medical device market applicants.
https://www.captis.com/wp-content/uploads/2019/04/emergo-1x1-2.jpg 150 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-04-09 03:00:332019-04-09 03:01:05Japan increases medical device registration fees
Login to CAPTIS with LinkedIn
(United States & Canada Toll Free)
EUROSPINE 2020
* - indicates required field
Archives Select Month December 2020 November 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 April 2018 March 2018 February 2018 January 2018 December 2017 November 2017 October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 December 2013 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 May 2013 April 2013 March 2013 February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009 May 2009 April 2009 March 2009 February 2009 January 2009 December 2008 November 2008 October 2008 September 2008 August 2008 July 2008 June 2008 May 2008 April 2008 March 2008 January 2008 December 2007 November 2007 October 2007 September 2007 August 2007 July 2007 June 2007 May 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006
Follow CAPTIS
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News
CAPTIS Newsletter
Call CAPTIS
© CAPTIS - Executive Search - 2017 - [email protected]
For Healthcare Executives
Legal & Privacy Notes, GDPR & Cookies Policy
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy